U.S. Markets closed

Applied Therapeutics, Inc. (APLT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
15.36+0.05 (+0.33%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close15.31
Open15.39
Bid13.21 x 800
Ask15.55 x 1000
Day's Range14.66 - 15.81
52 Week Range13.04 - 29.80
Volume166,588
Avg. Volume94,251
Market Cap400.61M
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-4.64
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.83
  • Simply Wall St.

    Is Applied Therapeutics (NASDAQ:APLT) Using Debt Sensibly?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • Benzinga

    Applied Therapeutics Stock Drops On Delayed NDA Submission For Its Lead Candidate

    Applied Therapeutics Inc (NASDAQ: APLT) has reported initial biomarker data from the pediatric ACTION-Galactosemia Kids study and baseline analysis of the 47 children enrolled in the study. Related Content: FDA Fast Track Review For AT-007 In Rare Metabolic Disorder. Galactosemia is a condition in which the body cannot use (metabolize) the simple sugar galactose. Pharmacokinetic analysis of AT-007 plasma drug levels at day 30 revealed that dosing could be further optimized by adjusting dose base

  • GlobeNewswire

    Applied Therapeutics Reports Initial Pediatric Biomarker Data from ACTION-Galactosemia Kids

    Substantial and statistically significant reduction in plasma galactitol Baseline analysis demonstrates clear relationship between plasma galactitol level and severity of disease in pediatric Galactosemia patients NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported initial biomar